Controlled release of minocycline HCl maintains therapeutic levels of antibiotic up to 21 days

Unique microsphere delivery system

How ARESTIN® Microspheres Work

ARESTIN® is a powder that contains the antibiotic minocycline Hydrochloride, or minocycline HCl, embedded in a polymer base that is easily absorbed by the body. It comes in easy-to-use, unit-dose cartridges that provide effective drug concentrations directly at the site of infection.

ARESTIN® (Minocycline-HCl) Microspheres at work

ARESTIN® microspheres release minocycline over time, and are completely reabsorbed into the body.

When ARESTIN® is inserted, it immediately adheres to the periodontal pocket. Moisture in the patient's mouth begins to break down (hydrolyze) the polymer, causing water-filled channels to form inside the microspheres. This allows a controlled, sustained release of minocycline.

Treatment with ARESTIN® helps kill the bacteria that underlie periodontal disease, to create a healthier environment.

About Minocycline HCl

ARESTIN® (minocycline HCl) microspheres, 1 mg contains the broad-spectrum antibiotic minocycline, a member of the tetracycline class of antibiotics.

Minocycline Effectively Treats Periodontal Pathogens

Minocycline achieves minimum inhibitory concentration levels well above those required for common periodontal pathogens. This effectively treats the harmful red complex bacteria that cause periodontal disease.

Other Benefits of Tetracycline Derivatives

Minocycline also inhibits enzymes and other molecules that destroy elements of the periodontium, including collagen, elastic fibers, proteoglycans, and fibroconectin.

For full safety information, click here.

See ARESTIN® in Action

ARESTIN® Mechanism of Action Video

ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Contact us with questions about your account or MyArestin.com